Journal
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcimb.2020.581345
Keywords
hepatitis B virus; Kampo; maoto; tropomyosin β chain (TPM2); cytoskeleton
Categories
Funding
- AMED [JP19fk0310101, JP20fk0310101]
- JSPS KAKENHI [18H02664, 18K19449]
- Takeda Science Foundation
- Senri Life Science Foundation
- Kobayashi International Scholarship Foundation
- Grants-in-Aid for Scientific Research [18H02664, 18K19449] Funding Source: KAKEN
Ask authors/readers for more resources
The study found that maoto has the potential to suppress hepatitis B virus production by interfering with the viral nucleocapsid incorporation. Additionally, the reduction of host gene TPM2 expression by maoto also leads to inhibition of virus production, suggesting TPM2 as a novel molecular target for anti-HBV drug development.
Worldwide, millions of people suffer from hepatitis B virus (HBV) infection, putting them at a high risk of death from liver cirrhosis and cancer. Although effective anti-HBV drugs have been developed, current drugs have some limitations, as most of them have a risk of significant side effects. Therefore, the discovery of safe and effective anti-HBV drugs is still needed. Natural compounds are considered sources of novel, safe and effective therapeutics. In this study, we screened a library of Kampos, traditional herbal medicines, for suppression of HBV production. Among them, we found that maoto reduced extracellular HBV DNA but not extracellular HBsAg during HBV infection, suggesting that it suppressed HBV production by interfering with HBV nucleocapsid incorporation into viral particles. Furthermore, we revealed that maoto reduced the expression of a host gene, Tropomyosin beta chain (TPM2), whose downregulation also suppressed HBV production, similarly to maoto. Since the safety of maoto has been already confirmed, maoto can be considered a candidate anti-HBV agent if the effect is confirmed in vivo. In addition, our findings also suggest TPM2 as a novel molecular target for the development of anti-HBV agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available